Autopsy report · NCT04329195

ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic

“insufficient recrutment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 44 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection

Interventions

1: discontinuation of RAS blocker therapy; 2: continuation of RAS blocker therapy

Participants

44

Sites

1

Countries

France

Trials that died the same way

• Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients
  “difficulty of recrutement” (67% match in meaning)
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
  “Insufficient Accrual” (66% match in meaning)
• Ropivacaine 0.75% Versus Levobupivacaine 0.5% for Conversion of Labour Epidural
  “Not able provide staff for recruting at present” (62% match in meaning)
• Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia
  “Insufficient staff” (59% match in meaning)
• Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers
  “Difficulty accruing” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.